Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 6/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9119279 | 0.92 | PNMT (0.46) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| SCHEMBL10238388 | 0.82 | PNMT (0.42) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| SCHEMBL3982958 | 0.75 | MAPT (0.40) | HTR6 | |
| SCHEMBL10253943 | 0.75 | HTR2A (0.48) | PNMTADRA2AADRA2BADRA2CHTR6 | |
| SCHEMBL3499450 | 0.75 | METAP1 (0.35) | ADRA2AHTR6 | |
| SCHEMBL6988847 | 0.75 | DRD2 (0.44) | — | |
| SCHEMBL19835515 | 0.75 | CA1 (0.39) | HTR6 | |
| SCHEMBL5366924 | 0.75 | ASIC3 (0.46) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| SCHEMBL31122821 | 0.74 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| SCHEMBL18454733 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014086316-A1 | SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-06-12 | — | — | WO | disclosed |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | ACKR3, CCL11, CCR7 | PNMT 3406/4885ADRA2A 1326/4885ADRA2B 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.